Quantcast

Halaven (Eribulin, E7389)


#1

The name of this drug was mentioned yesterday at the SFA Educational Conference because large trials (likely phase III) are scheduled to start sometimes soon. I had never heard of this name so I did my little search and found the results from the European phase II study :

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=40867

The response rate for synovial sarcoma is not very impressive unfortunately...


#2

Phase III trial of eribulin in soft tissue sarcoma shows overall survival benefit in primary endpoint:

http://checkorphan.org/news/phase-iii-trial-of-anticancer-agent-halaven-r-eribulin-in-soft-tissue-sarcoma-shows-overall-survival-benefit-in-primary-endpoint

It's not clear whether there was any patient with synovial sarcoma in this study. We'll have to wait for the data.

Results of the phase 2 trial are here:

http://www.ncbi.nlm.nih.gov/pubmed/21937277